Glecaprevir/Pibrentasvir for the Treatment of PTSD

Summary

An open-label pilot study to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Timeline

Start

2023-04-01

Primary completion

2024-04-15

Completion

2024-04-15

Drugs

Indications